Dana-Farber Cancer Institute | Strategic Alliance Partners

February 25, 2020

Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, director of Translational Research, and physician, Dana-Farber Cancer Institute, discusses the potential use of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

February 25, 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

February 21, 2020

Sara Tolaney, MD, MPH, reflects on the encouraging findings observed with CDK4/6 inhibitors in combination with endocrine therapy in the treatment of patients with hormone receptor-positive, HER2-negative breast cancer.

February 21, 2020

Jacqueline S. Garcia, MD,discusses how navitoclax differs from other agents in primary or secondary myelofibrosis.

February 19, 2020

Ziad Bakouny, MD, MSc, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

February 12, 2020

Nancy Lin, MD, discusses central nervous system–specific outcomes with neratinib (Nerlyx) in HER2-positive breast cancer.

February 11, 2020

Claire Manuszak, BS, discusses the rationale to combine prexasertib (LY2606368) and LY3300054 in patients with high-grade serous ovarian cancer.

February 07, 2020

David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, discusses the use of immunotherapy in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

February 04, 2020

Matthew S. Davids, MD, MMSc, director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses exciting data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

January 31, 2020

Irene Ghobrial, MD, discusses the combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone in smoldering multiple myeloma.

January 31, 2020

Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non­–small cell lung cancer.

January 31, 2020

Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.

January 31, 2020

Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non

January 30, 2020

Jacqueline S. Garcia, MD, discusses the design and findings of a phase II trial of navitoclax and details next steps for the BCL-XL/BCL-2 inhibitor.

January 30, 2020

David A. Braun, MD, PhD, discusses the evolution of immunotherapy in advanced renal cell carcinoma.

January 25, 2020

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

January 18, 2020

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.

January 17, 2020

Nikhil C. Munshi, MD, discusses the antitumor effect of NKTR-255 in patients with multiple myeloma.

January 17, 2020

Julia Rotow, MD, discusses updated data from the phase III ALEX trial in ALK-positive non–small cell lung cancer.

January 15, 2020

Nancy U. Lin, MD, discusses research focusing on CNS penetration in HER2-positive metastatic breast cancer.